Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
BACKGROUND: Active immunotherapy of cancer is based on the premise that the vaccine raises a
cytotoxic immune response to tumor-associated antigens, thereby destroying malignant cells
without harming normal cells.
IMA950 is a therapeutic multi-peptide vaccine containing 11 tumor-associated peptides
(TUMAPs) found in a majority of glioblastomas, and is designed to activate TUMAP-specific T
cells. The use of 11 TUMAPs increases the likelihood of a multi-clonal, highly specific
T-cell response against tumor cells leading to decreased likelihood of immune evasion of the
tumor by down-regulation of target antigens.
PURPOSE: The primary objective of this study is to determine the safety and tolerability of
IMA950 when given with cyclophosphamide, granulocyte macrophage-colony stimulating factor
(GM-CSF) and imiquimod in patients with glioblastoma and to determine if IMA950 shows
sufficient immunogenicity in these patients.
ELIGIBILITY: Patients with histologically proven GBMs who have completed radiotherapy, and
have stable disease following at least 4 cycles of adjuvant temozolomide.